New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications (Q34999538)

5 August 2017

1 reference

title

New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications (English)

1 reference

5 August 2017

Till Assmann

1 reference

5 August 2017

Thomas Ruzicka

series ordinal

1 reference

5 August 2017

publication date

1 September 2002

1 reference

5 August 2017

published in

Clinics in Dermatology

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

505-514

1 reference

Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Immunosuppressive effect of mycophenolic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment Of Psoriasis With Oral Mycophenolic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical application of mycophenolate mofetil in plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Investigation of the penetration behaviour of mycophenolate mofetil from a semisolid formulation into human skin ex-vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Mycophenolic acid in the treatment of psoriasis: long-term administration

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Mycophenolate is effective in the treatment of pemphigus vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Bullous pemphigoid treated with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Acquired epidermolysis bullosa with a highly varied clinical picture and successful treatment with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment of relapsing idiopathic nodular panniculitis (Pfeifer-Weber-Christian disease) with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment of atopic eczema with oral mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Dyshidrotic eczema treated with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Therapy of systemic lupus erythematosus: new agents and new evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

FK 506 for liver, kidney, and pancreas transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Anti-inflammatory effect of FK-506 on human skin mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus: the drug for the turn of the millennium?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus ointment for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus ointment improves psoriasis in a microplaque assay

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Erosive mucosal lichen planus: response to topical treatment with tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical tacrolimus for pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical tacrolimus for pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

Topical tacrolimus: treatment failure in a patient with alopecia areata

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2802%2900271-7

7 January 2021

10.1016/S0738-081X(02)00271-7

Identifiers

DOI

1 reference

5 August 2017

1 reference